Physician profile
Phillip Brackin
NPI 1598754640
$4,002.52
in general payments reported to CMS, 2019-2025
33 companies · $80.93 in 2025
The $80.93 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $1,148 · 2021: $1,378 · 2022: $162 · 2023: $16.47 · 2024: $15.94 · 2025: $80.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $113.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $484.96 | 2019-2022 | |
| Abbvie INC. | $316.76 | 2019-2022 | |
| Pfizer INC. | $278.66 | 2019-2025 | |
| Zyla Life Sciences, INC. | $249.28 | 2019 | |
| Janssen Biotech, INC. | $246.42 | 2019-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $243.68 | 2019-2022 | |
| Antares Pharma, INC. | $231.97 | 2019-2025 | Xyosted |
| Dendreon Pharmaceuticals LLC | $229.63 | 2019-2022 | |
| Allergan, INC. | $225.45 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $184.19 | 2020-2022 | |
| Endo Pharmaceuticals INC. | $153.98 | 2019-2021 | |
| Foundation Medicine, INC. | $132.99 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $111.06 | 2019-2022 | |
| Myovant Sciences INC. | $98.69 | 2021 | |
| Boston Scientific Corporation | $73.28 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $71.48 | 2019-2021 | |
| Acerus Pharmaceuticals Corporation | $68.86 | 2020-2021 | |
| Neotract INC. | $67.18 | 2019-2020 | |
| 180 Medical, INC. | $58.38 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $55.37 | 2019-2020 | |
| Urogen Pharma, INC. | $52.49 | 2021-2025 | |
| Clarus Therapeutics INC. | $42.43 | 2021 | |
| Urovant Sciences INC | $42.26 | 2021-2022 | |
| Procept Biorobotics Corporation | $42.19 | 2021 | |
| Axonics, INC. | $39.99 | 2021 | |
| Olympus America INC. | $33.04 | 2021-2022 | |
| Teleflex LLC | $29.38 | 2021 | |
| Merck Sharp & Dohme LLC | $28.44 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $27.00 | 2020-2021 | |
| Blue Earth Diagnostics | $25.76 | 2019-2021 | |
| Ambu INC. | $23.10 | 2020 | |
| Photocure INC | $18.86 | 2019 | |
| Verity Pharmaceuticals INC. | $15.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Brackin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.